NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Study for the NAPLEX exam with a comprehensive quiz featuring multiple-choice questions and in-depth explanations. Build your pharmacological knowledge and increase your chances of passing the pharmacist licensure examination!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

Alemtuzumab (Lemtrada) requires enrollment in what program due to safety concerns?

MEDWATCH Program
REMS Program
Patient Assistance Program
SAFE Rx Program

The correct answer is: REMS Program

Alemtuzumab (Lemtrada) requires enrollment in the REMS (Risk Evaluation and Mitigation Strategy) Program due to safety concerns. The REMS program is a strategy to manage known or potential serious risks associated with a drug product and is required for certain medications with significant safety concerns. By enrolling in the REMS program, healthcare providers and patients are educated about these risks and how to minimize them, ensuring safe use of the medication. This program includes elements such as training, certification, dispensing restrictions, patient monitoring, and follow-up. The other options mentioned are not specifically designed to address safety concerns related to specific medications like the REMS program.